3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other
1
Breast
1
Conditions
Pain
3
Neuralgia
3
Breast Neoplasms
3
Seizures
1
Pinealoma
1
Oligodendroglioma
1
Obesity
1
Neuroectodermal Tumors, Primitive
1
Neoplasms
1
Myotoxicity
1
Meningioma
1
Medulloblastoma
1
Lymphoma
1
Inflammation
1
Head and Neck Neoplasms
1
Gliosarcoma
1
Glioma
1
Glioblastoma
1
Ependymoma
1
Earache
1
Drug-Related Side Effects and Adverse Reactions
1
Central Nervous System Neoplasms
1
Brain Neoplasms
1
Astrocytoma
1
Agnosia
1
Interventions
epigallocatechin gallate
2
XENP 1595
2
Etanercept
2
Ascorbic Acid
2
salicylsalicylic acid
1
microcrystalline cellulose
1
ginger extract
1
dapagliflozin
1
cytisine
1
Tablets
1
Sulindac
1
Spirometry
1
Specimen Handling
1
Sodium Salicylate
1
Radiotherapy, Conformal
1
Pregabalin
1
Omeprazole
1
Losartan
1
Ketorolac
1
Interleukin 1 Receptor Antagonist Protein
1
Infliximab
1
Hematologic Tests
1
Diet Therapy
1
Atorvastatin
1
Aspirin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Inflammation
×
Pregabalin
×
Clear all
NCT06150898
2025-06-13
KePreSt
Jules Bordet Institute
Phase 2
Recruiting
112 enrolled